InSysBio announces the upcoming webinar on the New Data Annotation Service for CYTOCON DB & fIVE DB on May 19, 2026, 16:00 CEST / 10:00 ET (Microsoft Teams).
Stop mining PubMed. Start modeling.
Before the first equation is written, QSP modelers face a data problem. Sourcing reliable baseline concentrations, extracting kinetic parameters from in vitro studies, standardizing units across dozens of papers, deciding which values to trust — this work typically consumes 4–8 weeks per project, delays model development, and inflates costs.
InSysBio has built two purpose-designed databases to address this bottleneck.
CYTOCON DB is a manually curated database of human in vivo cell and cytokine concentrations: 551 disease types, 253 tissues, 813 molecules, 301 cell types, and over 112,000 standardized data points extracted from nearly 3,000 published sources. Content grows by approximately 1,500 values per month.
fIVE DB captures quantitative parameters derived from in vitro and ex vivo experiments on cell processes — secretion, proliferation, cell death, migration, differentiation, and cytokine degradation — with over 43,000 parameters extracted from 2,247 sources, pre-processed into forms directly usable in mathematical models.
For projects requiring data beyond existing database coverage — rare indications, novel targets, or expanded parameter sets — InSysBio's Data Annotation Service delivers custom, expert-curated datasets within 30 days.
This webinar walks through what each database contains, how the data maps to QSP calibration and virtual patient workflows, and when custom annotation fills the gaps.
WHAT YOU'LL LEARN
Speaker: Vladislav Leonov, CYTOCON DB and fIVE DB Manager.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | May 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
1.
15 May 2025 15:07
15th InSysBio’s Annual Internal Scientific Meeting
InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
|
16
|
17
|
18
|
|
19
|
20
|
21
1.
21 May 2025 16:55
InSysBio to take part in PAGE 2025
InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
1.
30 May 2025 15:23
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
|
31
| |
Thank you for your message! We will get back to you shortly.
